Parag Roy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Parag Roy has a total of 55 co-authors. Here are the top co-authors by number of shared publications:
- Animesh Ghosh
Solid State Pharmaceutics Research Laboratory, Department of Pharmaceutical Sciences and Technology, Birla Institute of Technology Mesra, Jharkhand, 835215, India
9 shared publications - Noopur Pandey
Solid State Pharmaceutics Research Laboratory, Department of Pharmaceutical Sciences & Technology, Birla Institute of Technology, Mesra, Ranchi 835215, Jharkhand, India
5 shared publications Siddhartha S. Baisya
Department of Chemistry, University of North Bengal, Siliguri 734 013, India
5 shared publicationsNimmy Kumari
Solid State Pharmaceutics Research Laboratory, Department of Pharmaceutical Sciences and Technology
4 shared publications- Oisin N. Kavanagh
Newcastle University
3 shared publications - Adam A. L. Michalchuk
School of Chemistry, University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK
2 shared publications
Latest Publications
- Open Access
Investigating 24-Hour Urine Expected Ranges of Non-Kidney Stone Formers: an EAU Endourology Research Group Systematic Review and Meta-Analysis
Background and Objective: There is substantial variation in reference ranges for 24-hour urine collections, leading to diagnostic uncertainty. We aimed to curate robust evidence for expected ranges of 24-hour urine collections in the non-kidney stone forming population. Methods: We performed a systematic review (PROSPERO ID: CRD42024590784) of healthy adults without kidney stone disease undergoing 24-hour urine collections. Each component was meta-analysed in R, stratified by age, sex and ancestry, meta-regression and sensitivity analyses for study design, collection completeness and bias. An explicit eight-branch decision framework selected the recommended analysis per component. Expected ranges were derived from the pooled SD (95% interval); evidence was quantified by GRADE. Key Findings and Limitations: Seventy-two articles were included (10,284 participants). Expected ranges (mmol / 24 h unless stated): volume 1.0–2.5L, calcium 1.9–6.2, oxalate 0.2–0.6 (men) / 0.2–0.4 (women), urate 2.0–5.1(men)/2.3–3.5(women), pH 5.6–6.3, citrate 1.2–4.5, creatinine 12.2– 16.3(men)/7.2–12.6(women), phosphate 19–26, sodium 98–253, potassium 28–77, magnesium 3.1–4.8, ammonium 28–46(men)/20–40(women), chloride 84–218, sulphate 17–26(men)/7–30(women), urea 234–445. Principal limitations were: high between-study heterogeneity (I 2 >95% for most components) and assay/laboratory variability (most marked for citrate and potassium). Conclusions and Clinical Implications: This is the first study to attempt a robust characterization of 24-hour urine expected ranges using meta-analysis. Six of the derived expected ranges (pH, oxalate, magnesium, sulphate, urate, creatinine) were broadly concordant with existing reference ranges, providing an evidence base for those specific components. Take Home Message: This study establishes expected 24-hour urine values in a non-stone-forming population and provides empirical support for the derivation of reference ranges for several common urine analytes. I t also provides a repository of data for further analyses. Patient summary: The existing 24-hour urine reference ranges are poorly characterised. These are important as they are used by clinicians to diagnose and guide treatment for conditions predisposing to kidney stone formation. We have robustly determined expected ranges for people without kidney stones after reviewing existing studies in more than 10,000 people. For several urine components the available data remain limited, and our ranges should be revisited as more evidence accumulates.
Open AccessInvestigating 24-Hour Urine Expected Ranges of Non-Kidney Stone Formers: an EAU Endourology Research Group Systematic Review and Meta-Analysis
Background and Objective: There is substantial variation in reference ranges for 24-hour urine collections, leading to diagnostic uncertainty. We aimed to curate robust evidence for expected ranges of 24-hour urine collections in the non-kidney stone forming population. Methods: We performed a systematic review (PROSPERO ID: CRD42024590784) of healthy adults without kidney stone disease undergoing 24-hour urine collections. Each component was meta-analysed in R, stratified by age, sex and ancestry, meta-regression and sensitivity analyses for study design, collection completeness and bias. An explicit eight-branch decision framework selected the recommended analysis per component. Expected ranges were derived from the pooled SD (95% interval); evidence was quantified by GRADE. Key Findings and Limitations: Seventy-two articles were included (10,284 participants). Expected ranges (mmol / 24 h unless stated): volume 1.0–2.5L, calcium 1.9–6.2, oxalate 0.2–0.6 (men) / 0.2–0.4 (women), urate 2.0–5.1(men)/2.3–3.5(women), pH 5.6–6.3, citrate 1.2–4.5, creatinine 12.2– 16.3(men)/7.2–12.6(women), phosphate 19–26, sodium 98–253, potassium 28–77, magnesium 3.1–4.8, ammonium 28–46(men)/20–40(women), chloride 84–218, sulphate 17–26(men)/7–30(women), urea 234–445. Principal limitations were: high between-study heterogeneity (I 2 >95% for most components) and assay/laboratory variability (most marked for citrate and potassium). Conclusions and Clinical Implications: This is the first study to attempt a robust characterization of 24-hour urine expected ranges using meta-analysis. Six of the derived expected ranges (pH, oxalate, magnesium, sulphate, urate, creatinine) were broadly concordant with existing reference ranges, providing an evidence base for those specific components. Take Home Message: This study establishes expected 24-hour urine values in a non-stone-forming population and provides empirical support for the derivation of reference ranges for several common urine analytes. I t also provides a repository of data for further analyses. Patient summary: The existing 24-hour urine reference ranges are poorly characterised. These are important as they are used by clinicians to diagnose and guide treatment for conditions predisposing to kidney stone formation. We have robustly determined expected ranges for people without kidney stones after reviewing existing studies in more than 10,000 people. For several urine components the available data remain limited, and our ranges should be revisited as more evidence accumulates.
- Open Access
- 14 November 2025
- Published by Elsevier in European Journal of Pharmaceutics and Biopharmaceutics
- Vol. 218, 114933
A strategy to prevent ciprofloxacin induced corneal toxicity
- 14 November 2025
- Published by Elsevier in European Journal of Pharmaceutics and Biopharmaceutics
- Vol. 218, 114933
Open AccessA strategy to prevent ciprofloxacin induced corneal toxicity
- Open Access
- 6 October 2025
- Published by International Union of Crystallography (IUCr) in Acta Crystallographica Section C Structural Chemistry
- Vol. 81 (11) , 607-613
Crystallographic and physicochemical characterization of salcaprozoic acid: a structural basis for SNAC-enabled drug delivery systems
Salcaprozate sodium (SNAC) is a clinically approved oral permeation enhancer, notably used in the formulation of oral semaglutide. Despite its pharmaceutical importance, the crystallographic information of SNAC or its free acid form, salcaprozoic acid {systematic name: 8-[(2-hydroxyphenyl)formamido]octanoic acid, C 15 H 21 NO 4 , denoted HNAC}, has not been reported previously. Here, we present the first crystallographic and physicochemical characterization of HNAC using single-crystal X-ray diffraction and complementary analytical techniques. The structure reveals the molecular conformation, hydrogen-bonding network and packing features of HNAC, supported by a complementary solid-state dataset. These findings provide fundamental insights into the structural and physicochemical properties of this physiologically relevant form of SNAC.
- 6 October 2025
- Published by International Union of Crystallography (IUCr) in Acta Crystallographica Section C Structural Chemistry
- Vol. 81 (11) , 607-613
Open AccessCrystallographic and physicochemical characterization of salcaprozoic acid: a structural basis for SNAC-enabled drug delivery systems
Salcaprozate sodium (SNAC) is a clinically approved oral permeation enhancer, notably used in the formulation of oral semaglutide. Despite its pharmaceutical importance, the crystallographic information of SNAC or its free acid form, salcaprozoic acid {systematic name: 8-[(2-hydroxyphenyl)formamido]octanoic acid, C 15 H 21 NO 4 , denoted HNAC}, has not been reported previously. Here, we present the first crystallographic and physicochemical characterization of HNAC using single-crystal X-ray diffraction and complementary analytical techniques. The structure reveals the molecular conformation, hydrogen-bonding network and packing features of HNAC, supported by a complementary solid-state dataset. These findings provide fundamental insights into the structural and physicochemical properties of this physiologically relevant form of SNAC.
- 9 May 2025
- Published by American Chemical Society (ACS) in Crystal Growth & Design
- Vol. 25 (10) , 3425-3440
Elucidating the Mechanistic Shortcomings of Acetazolamide Cocrystals in Harnessing the Anticipated Solubility and Permeability Advantages
- 9 May 2025
- Published by American Chemical Society (ACS) in Crystal Growth & Design
- Vol. 25 (10) , 3425-3440
Elucidating the Mechanistic Shortcomings of Acetazolamide Cocrystals in Harnessing the Anticipated Solubility and Permeability Advantages
- 7 September 2023
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 20 (10) , 5226-5239
Study on Sulfamethoxazole–Piperazine Salt: A Mechanistic Insight into Simultaneous Improvement of Physicochemical Properties
Multidrug salts represent more than one drug in a crystal lattice and thus could be used to deliver multiple drugs in a single dose. It showcases unique physicochemical properties in comparison to individual components, which could lead to improved efficacy and therapeutic synergism. This study presents the preparation and scale-up of sulfamethoxazole-piperazine salt, which has been thoroughly characterized by X-ray diffraction and thermal and spectroscopic analyses. A detailed mechanistic study investigates the impact of piperazine on the microenvironmental pH of the salt and its effect on the speciation profile, solubility, dissolution, and diffusion profile. Also, the improvement in the physicochemical properties of sulfamethoxazole due to the formation of salt was explored with lattice energy contributions. A greater ionization of sulfamethoxazole (due to pH changes contributed by piperazine) and lesser lattice energy of sulfamethoxazole-piperazine contributed to improved solubility, dissolution, and permeability. Moreover, the prepared salt addresses the stability issues of piperazine and exhibits good stability behavior under accelerated stability conditions. Due to the improvement of physicochemical properties, the sulfamethoxazole-piperazine salt demonstrates better pharmacokinetic parameters in comparison to sulfamethoxazole and provides a strong suggestion for the reduction of dose. The following study suggests that multidrug salts can concurrently enhance the physicochemical properties of drugs and present themselves as improved fixed-dose combinations.
- 7 September 2023
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 20 (10) , 5226-5239
Study on Sulfamethoxazole–Piperazine Salt: A Mechanistic Insight into Simultaneous Improvement of Physicochemical Properties
Multidrug salts represent more than one drug in a crystal lattice and thus could be used to deliver multiple drugs in a single dose. It showcases unique physicochemical properties in comparison to individual components, which could lead to improved efficacy and therapeutic synergism. This study presents the preparation and scale-up of sulfamethoxazole-piperazine salt, which has been thoroughly characterized by X-ray diffraction and thermal and spectroscopic analyses. A detailed mechanistic study investigates the impact of piperazine on the microenvironmental pH of the salt and its effect on the speciation profile, solubility, dissolution, and diffusion profile. Also, the improvement in the physicochemical properties of sulfamethoxazole due to the formation of salt was explored with lattice energy contributions. A greater ionization of sulfamethoxazole (due to pH changes contributed by piperazine) and lesser lattice energy of sulfamethoxazole-piperazine contributed to improved solubility, dissolution, and permeability. Moreover, the prepared salt addresses the stability issues of piperazine and exhibits good stability behavior under accelerated stability conditions. Due to the improvement of physicochemical properties, the sulfamethoxazole-piperazine salt demonstrates better pharmacokinetic parameters in comparison to sulfamethoxazole and provides a strong suggestion for the reduction of dose. The following study suggests that multidrug salts can concurrently enhance the physicochemical properties of drugs and present themselves as improved fixed-dose combinations.
- 24 March 2023
- Published by American Chemical Society (ACS) in Crystal Growth & Design
- Vol. 23 (4) , 2470-2484
Polymorph Screening of the Antitumor Drug Ripretinib─Selective Preference of Dimer Synthons
- 24 March 2023
- Published by American Chemical Society (ACS) in Crystal Growth & Design
- Vol. 23 (4) , 2470-2484
Polymorph Screening of the Antitumor Drug Ripretinib─Selective Preference of Dimer Synthons
- 19 December 2022
- Published by American Chemical Society (ACS) in Crystal Growth & Design
- Vol. 23 (1) , 1-5
Molecular Docking of Pharmaceutical Cocrystal As a Ligand: Do We Need to Rethink?
- 19 December 2022
- Published by American Chemical Society (ACS) in Crystal Growth & Design
- Vol. 23 (1) , 1-5
Molecular Docking of Pharmaceutical Cocrystal As a Ligand: Do We Need to Rethink?
- 8 November 2022
- Published by Taylor & Francis in Pharmaceutical Development and Technology
- Vol. 27 (10) , 989-998
Development of ezetimibe eutectic with improved biopharmaceutical and mechanical properties to design an optimized oral solid dosage formulation
Eutectics are multicomponent systems which are an alternative to the conventional techniques for modulating the biopharmaceutical properties of a pharmaceutical. Ezetimibe is a hypocholesterolemic agent with limited dissolution, poor water solubility, and subsequently demonstrates low oral bioavailability. Additionally, ezetimibe exhibits poor mechanical properties, leading to difficulties in developing dosage forms through direct compression. The present work highlights the applicability of eutectics in the simultaneous improvement of physicochemical along with mechanical properties of ezetimibe. A pharmaceutical eutectic of ezetimibe with succinimide was prepared by mechanochemical grinding and thoroughly characterized using thermoanalytical, X-ray diffraction, and spectroscopic methods. Intrinsic dissolution rate and pharmacokinetic analysis were also performed for ezetimibe-succinimide eutectic in contrast to pure ezetimibe. The eutectic demonstrated ∼2-fold increase in the solubility and dissolution rate. In pharmacokinetic studies, the area under the curve (AUC) for ETZ-SUC eutectic (28.03 ± 2.22 ng*h/mL) was found to be higher than ETZ (8.98 ± 0.36 ng*h/mL), indicating improved oral bioavailability for eutectics. Also, it was observed that enhanced material functionality aids in designing directly compressed tablets, where the eutectic formulation showed an improved dissolution profile over the ezetimibe formulation. The study demonstrates that eutectic conglomerates could be utilized to develop ideal oral solid dosage formulations. Graphical Abstract
- 8 November 2022
- Published by Taylor & Francis in Pharmaceutical Development and Technology
- Vol. 27 (10) , 989-998
Development of ezetimibe eutectic with improved biopharmaceutical and mechanical properties to design an optimized oral solid dosage formulation
Eutectics are multicomponent systems which are an alternative to the conventional techniques for modulating the biopharmaceutical properties of a pharmaceutical. Ezetimibe is a hypocholesterolemic agent with limited dissolution, poor water solubility, and subsequently demonstrates low oral bioavailability. Additionally, ezetimibe exhibits poor mechanical properties, leading to difficulties in developing dosage forms through direct compression. The present work highlights the applicability of eutectics in the simultaneous improvement of physicochemical along with mechanical properties of ezetimibe. A pharmaceutical eutectic of ezetimibe with succinimide was prepared by mechanochemical grinding and thoroughly characterized using thermoanalytical, X-ray diffraction, and spectroscopic methods. Intrinsic dissolution rate and pharmacokinetic analysis were also performed for ezetimibe-succinimide eutectic in contrast to pure ezetimibe. The eutectic demonstrated ∼2-fold increase in the solubility and dissolution rate. In pharmacokinetic studies, the area under the curve (AUC) for ETZ-SUC eutectic (28.03 ± 2.22 ng*h/mL) was found to be higher than ETZ (8.98 ± 0.36 ng*h/mL), indicating improved oral bioavailability for eutectics. Also, it was observed that enhanced material functionality aids in designing directly compressed tablets, where the eutectic formulation showed an improved dissolution profile over the ezetimibe formulation. The study demonstrates that eutectic conglomerates could be utilized to develop ideal oral solid dosage formulations. Graphical Abstract
- 15 March 2022
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 19 (5) , 1557-1572
Investigating the Role of the Reduced Solubility of the Pirfenidone–Fumaric Acid Cocrystal in Sustaining the Release Rate from Its Tablet Dosage Form by Conducting Comparative Bioavailability Study in Healthy Human Volunteers
Pirfenidone (PFD) is the first pharmacological agent approved by the US Food and Drug Administration (FDA) in 2014 for the treatment of idiopathic pulmonary fibrosis (IPF). The recommended daily dosage of PFD in patients with IPF is very high (2403 mg/day) and must be mitigated through additives. In the present work, sustained-release (SR) formulations of the PFD-FA cocrystal of two different strengths such as 200 and 600 mg were prepared and its comparative bioavailability in healthy human volunteers was studied against the reference formulation PIRFENEX (200 mg). A single-dose pharmacokinetic study (200 mg IR vs 200 mg SR) demonstrated that the test formulation exhibited lower Cmax and Tmax in comparison to the reference formulation, which showed that the cocrystal behaved like an SR formulation. Further in the multiple-dose comparative bioavailability study (200 mg IR thrice daily vs 600 mg SR once daily), the test formulation was found bioequivalent to the reference formulation. In conclusion, the present study suggests that cocrystallization offers a promising strategy to reduce the solubility of PFD and opens the door for potential new dosage forms of this important pharmaceutical.
- 15 March 2022
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 19 (5) , 1557-1572
Investigating the Role of the Reduced Solubility of the Pirfenidone–Fumaric Acid Cocrystal in Sustaining the Release Rate from Its Tablet Dosage Form by Conducting Comparative Bioavailability Study in Healthy Human Volunteers
Pirfenidone (PFD) is the first pharmacological agent approved by the US Food and Drug Administration (FDA) in 2014 for the treatment of idiopathic pulmonary fibrosis (IPF). The recommended daily dosage of PFD in patients with IPF is very high (2403 mg/day) and must be mitigated through additives. In the present work, sustained-release (SR) formulations of the PFD-FA cocrystal of two different strengths such as 200 and 600 mg were prepared and its comparative bioavailability in healthy human volunteers was studied against the reference formulation PIRFENEX (200 mg). A single-dose pharmacokinetic study (200 mg IR vs 200 mg SR) demonstrated that the test formulation exhibited lower Cmax and Tmax in comparison to the reference formulation, which showed that the cocrystal behaved like an SR formulation. Further in the multiple-dose comparative bioavailability study (200 mg IR thrice daily vs 600 mg SR once daily), the test formulation was found bioequivalent to the reference formulation. In conclusion, the present study suggests that cocrystallization offers a promising strategy to reduce the solubility of PFD and opens the door for potential new dosage forms of this important pharmaceutical.
- 13 October 2020
- Published by Royal Society of Chemistry (RSC) in CrystEngComm
- Vol. 22 (42) , 6958-6974
Progress on cocrystallization of poorly soluble NME's in the last decade
Cocrystallization of pharmaceuticals has been an exciting field of interest to both academia and industries, demonstrated from its increasing growth rate of publications, patents, and marketed formulations.
- 13 October 2020
- Published by Royal Society of Chemistry (RSC) in CrystEngComm
- Vol. 22 (42) , 6958-6974
Progress on cocrystallization of poorly soluble NME's in the last decade
Cocrystallization of pharmaceuticals has been an exciting field of interest to both academia and industries, demonstrated from its increasing growth rate of publications, patents, and marketed formulations.